期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2020
卷号：117
期号：48
页码：30027-30028
DOI：10.1073/pnas.2011616117
出版社：The National Academy of Sciences of the United States of America
摘要：We appreciate that Yang et al. (1) are concerned about the safety concerns regarding the use of tocilizumab and the combination usage with glucocorticoids in COVID-19 patients. We propose that tocilizumab can effectively treat severe COVID-19 patients (2); such effectiveness has also been confirmed by many other groups (3, 4). Whether glucocorticoids usage is suitable for COVID-19 has been controversial for a long time. Some researchers do not recommend it to treat severe acute respiratory syndrome coronavirus 2-induced lung injury or shock (5). But a clinical trial from Oxford University reported that dexamethasone could reduce the 28-d mortality of COVID-19 patients with invasive mechanical ventilation or oxygen, but not of patients without respiratory support (6 … [↵][1]2To whom correspondence may be addressed.
